PURPOSE: To evaluate the long-term impact of Medifast meal-replacement supplements (MMRS) combined with appetite suppressant medication (ASM) among participants who received 52 weeks of treatment. METHODS: We conducted a systematic program evaluation of weight loss data from a medically-supervised weight control program combining the use of MMRS and ASM. Data were obtained and analyzed from 1,351 patient (BMI=25) medical charts who had participated for at least 12 weeks of treatment. Outcomes included weight loss (kg) and percent weight loss from baseline and at 12, 24, and 52 weeks. Both completers and intention-to-treat analyses were conducted. Completers’ (i.e., those with complete data for 52 weeks) outcomes were evaluated after stratification for reported adherence to the MMRS and ASM. RESULTS: Participants who completed 52 weeks of treatment experienced substantial weight losses at 12 (-9.4±5.7 kg), 24 (-12.0±8.1 kg), and 52 weeks (-12.4±9.2 kg) and all measures were significantly different from baseline weight (p<0.001 for all contrasts) for both true completers (n=324) and for ITT analysis (n=1,351). Fifty percent of patients remained in the program at 24 weeks and nearly 25% were still participating at one year. CONCLUSIONS: This weight loss program using a combination of MMRS and ASM produced significant and sustained weight losses at 52 weeks. Results were better than those typically reported for obesity pharmacotherapy in both short- and long-term studies and also better than those reported for partial meal replacement programs. Program retention at one year was similar to that reported in many controlled drug trials and better than most commercial programs reported in the literature.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Marketdata Enterprises 2005. The US weight loss & diet control market. 8th edition. URL: http://www.marketresearch.com/product/display.asp?product=1075148. Accessed 11/14/2006.
Tsai A.G., Wadden T.A.: Systematic review: An evaluation of major commercial weight loss programs in the United States. Ann. Intern. Med., 142, 56–66, 2005.
Wang S.S., Wadden T.A., Womble L.G., Nonas C.A.: What consumers want to know about commercial weight-loss programs: A pilot investigation. Obes. Res., 11, 48–53, 2003.
Cheskin L.J., Mitchell A.M., Lewis R.A., Jhaveri A.D., Yep M.A.: Efficacy of two diet plans designed for people with type 2 diabetes on weight and health measures. Presented at the American Diabetes Association’s 65th Annual Scientific Session, San Diego, CA, 2005.
Heshka S., Anderson J.W., Atkinson R.L., Greenway F.L., Hill J.O., Phinney S.D., Kolotkin R.L., Miller-Kovach K., Pi-Sunyer F.X.: Weight loss with self-help compared with a structured commercial program: A randomized trial. JAMA, 289, 1792–1798, 2003.
Medifast 2006. Corporate website. URL: http://www.medifast1.com/webpromo/. Accessed 12/11/2006.
Truby H., Baic S., deLooy A., Fox K.R., Livingstone M.B., Logan C.M., MacDonald I.A., Morgan L.M., Taylor M.A., Millward D.J.: Randomized controlled trial of four commercial weight loss programmes in the UK: initial findings from the BBC diet trials. B.M.J., 332, 1309–1314, 2006.
Wadden T.A., Berkowitz R.I., Womble L.G., Sarwer D.B., Phelan S., Cato R.K., Hesson L.A., Osei S.Y., Kaplan R., Stunkard A.J.: Randomized trial of lifestyle modification and pharmacotherapy for obesity. N. Engl. J. Med., 353, 2111–2120, 2005.
Poston W.S.C., Haddock C.K., Pinkston M.M., Pace P., Reeves R.S., Karakoc N., Jones P., Foreyt J.P.: Evaluation of a primary care-oriented brief counselling intervention for obesity with and without orlistat. J. Intern. Med., 260, 388–398, 2006.
Padwal R., Li S.K., Lau D.C.W.: Long-term pharmacotherapy for overweight and obesity: A systematic review and meta-analysis of randomized controlled trials. Int. J. Obes. Relat. Metab. Disord., 27, 1437–1446, 2003.
Volkmar F.R., Stunkard A.J., Woolston J., Bailey R.A.: High attrition rates in commercial weight loss reduction programs. Arch. Intern. Med., 141, 426–428, 1981.
Finley C.E., Barlow C.E., Greenway F.L., Rock C.L., Rolls B.J., Blair S.N.: Retention rates and weight loss in a commercial weight loss program. Int. J. Obes. Relat. Metab. Disord., 31, 292–298, 2007.
Haddock C.K., Poston W.S.C., Dill P.L., Foreyt J.P., Ericsson M.: Pharmacotherapy for obesity: A quantitative analysis of four decades of published randomized clinical trials. Int. J. Obes. Relat. Metab. Disord., 26, 262–273, 2002.
Heymsfield S.B., van Mierlo C.A.J., van der Knaap H.C.M., Heo M., Frier H.I.: Weight management using a meal replacement strategy: Meta and pooling analysis from six studies. Int. J. Obes. Relat. Metab. Disord., 27, 537–549, 2003.
About this article
Cite this article
Haddock, C.K., Poston, W.S.C., Foreyt, J.P. et al. Effectiveness of Medifast supplements combined with obesity pharmacotherapy: A clinical program evaluation. Eat Weight Disord 13, 95–101 (2008). https://doi.org/10.1007/BF03327609
- primary care
- weight loss
- meal replacement